Antithrombotic drugs market will generate over $20bn by 2018, predicts new analysis

Wednesday 2 April 2014, Amsterdam

A new report forecasts the world antithrombotic drug market will be worth over $20.4bn by 2018. That segment of the pharmaceuticals industry generated $17.4bn in 2013, according to Antithrombotic Drugs: World Industry and Market Prospects 2014-2024.

The new report forecasts the global market for antithrombotic drugs will expand steadily during the first half of that forecast period, recovering from the decline seen in 2013 as a result of generic competition for the market-leading drugs, Plavix and Lovenox. That expansion will be driven by novel oral anticoagulants, two of which achieved blockbuster status. The strength of the antithrombotic drug market stems from the high profile of the conditions associated with thrombotic disease, which need long term drug treatment, generating a high volume of repeat sales.

Jennifer Taylor, a pharmaceutical industry analyst, said: “The antithrombotic drug industry is changing. The market-leading drug, Plavix, which became the second-highest selling drug of all time in 2011, with revenue over $9.6bn, faces generic competition. In 2013 this resulted in a contraction of the global antithrombotic drugs market.

“However, the increasing penetration of the novel oral anticoagulants Pradaxa and Xarelto is driving growth in the market. Those products each generated over $1.7bn in 2013. As a result of their success, the antithrombotic drug industry will achieve revenue growth in 2014 and will begin to recover from the drop in Plavix sales. However, the uptake of novel oral anticoagulants has been slower than expected. Will the antithrombotic drug market again reach the revenue heights of 2011?

“Another difficulty in that industry is failures in clinical trials. The R&D pipeline is being eroded; it is weakening. And many existing products face patent expiry during our forecast period, 2014-2024. Will the compounds in development be sufficient to offset these losses? Yes, 2014 to 2024 forms an exciting time in the antithrombotic drugs industry.”

The new report shows revenue forecasts to 2024 at overall world market, submarket, product and national level. It forecasts the segments antiplatelet drugs, anticoagulants and fibrinolytics.

The analysis includes forecasting of main subclasses for anticoagulant drugs:

• Heparins
• Direct thrombin inhibitors
• Direct factor Xa inhibitors
• Vitamin K antagonists
• Others treatments.

That study also forecasts revenues of 15 leading products, including Plavix, Lovenox, Pradaxa, Xarelto, Activase and Effient. The report analyses the national markets of the US, Japan, Germany, France, Italy, the UK, Spain (EU5), Brazil, Russia, India and China (BRIC), too, and provides revenue forecasts for those countries.

The report explores companies such as Sanofi, Bristol-Myers Squibb, Boehringer Ingelheim, Johnson & Johnson and Bayer, including their research and development (R&D). It also gives four interviews with other authorities on that field.

Antithrombotic Drugs: World Industry and Market Prospects 2014-2024 adds to the portfolio of reports on industries and markets in healthcare. Together those studies assess commercial potentials of pharmaceuticals, diagnostics and medical devices.